Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 17, 2024European Heart Journal - Cardiovascular PharmacotherapyOpen Access

2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Significant advances occurred since the 2019 guidelines, warranting an updated summary of key pharmacotherapy recommendations for chronic coronary syndromes.

Population

Patients with chronic coronary syndromes

Design

Guideline summary

Authors

MGMattía GalliFGFelice GragnanoCVChristiaan Vrints

Discussion

Loading...

Member takes

Overview

New CCS classification may aid risk stratification; leaves open validation against outcomes in prospective data.

Structured PICO

P
Population
Patients with chronic coronary syndromes (CCS), including subgroups with prior myocardial infarction (MI), prior percutaneous coronary intervention (PCI), high bleeding risk, statin intolerance, type 2 diabetes mellitus (T2DM), and overweight or obesity (BMI ≥27 kg/m2).
I
Intervention
Updated pharmacotherapy recommendations including clopidogrel 75 mg daily monotherapy, shortened 1-3 month DAPT, bempedoic acid 180 mg daily, oral SGLT2 inhibitors, GLP-1 receptor agonists (semaglutide up to 2.4 mg once-weekly subcutaneously), low-dose colchicine 0.5 mg daily, and tailored antianginal drug combinations.

The 2024 ESC guidelines on chronic coronary syndromes provide significant updates to secondary prevention pharmacotherapy, expanding the roles of clopidogrel monotherapy, bempedoic acid, SGLT2 inhibitors, GLP-1 receptor agonists, and low-dose colchicine.

Cite This Study

Galli et al. (2024) studied this question.

synapsesocial.com/papers/6a715bf8ac440176ef2a0a88https://doi.org/10.1093/ehjcvp/pvae069
View Full Paper
Ask AI
Bookmark
Share